Skip to main content
TipRanks
Go Ultimate75% OFF

Mediwelcome Healthcare Management & Technology Inc. (2159) AI Stock Analysis

1 Followers
HK:2159

Mediwelcome Healthcare Management & Technology Inc.

(HKEX:2159)

Select Model
Rating:55Neutral
Price Target:HKD 1.50â–¼(-5.06% Downside)
Action:reiterated
Date:11/07/26

The overall score of 55 reflects a company in the early stages of a financial turnaround, supported by a low valuation. The most significant positive factor is the strong revenue growth and return to profitability, which is partially offset by weak technical momentum and fragile cash flow quality. The low P/E ratio provides a valuation cushion, but the absence of positive technical signals and dividends limits upside conviction.

Positive Factors
Revenue reboundThe sharp 2025 revenue rebound indicates renewed demand for the company’s healthcare and eldercare-related services and technology. If maintained, stronger top-line scale can support operating leverage, reinvestment in solutions, and improved competitive positioning over the coming quarters.
Negative Factors
Very thin operating marginAn operating margin of only 0.39% leaves little buffer against cost increases, slower growth, or execution setbacks. The company therefore needs sustained revenue expansion or meaningful efficiency gains before its operating model can produce consistently resilient profits.

Mediwelcome Healthcare Management & Technology Inc. (2159) vs. iShares MSCI Hong Kong ETF (EWH)

-20%0%20%40%60%80%100%HK:2159+32.77%EWH+4.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 524.68M
Dividend Yield
―
Average Volume (3M)
115.98K
Price to Earnings (P/E)
9.8
Beta (1Y)
0.71
Revenue Growth
91.32%
EPS Growth
―
Country
Hong Kong
Employees
150
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Mediwelcome Healthcare Management & Technology Inc. Business Overview & Revenue Model

Company Description

As an investment holding entity, Mediwelcome Healthcare Management & Technology Inc. delivers comprehensive marketing solutions for the healthcare sector within the People's Republic of China. Its service portfolio encompasses medical conference orga...

Mediwelcome Healthcare Management & Technology Inc. Financial Statement Overview

Summary

The company shows a strong revenue rebound and a return to profitability, but margins remain thin and historical volatility tempers the outlook. The balance sheet is improving with lower leverage, yet a declining asset base and modest cash generation indicate the turnaround is still fragile.

Income Statement

55Neutral

Balance Sheet

50Neutral

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue568.69M468.02M321.56M331.31M323.37M708.36M
Gross Profit141.70M94.71M51.00M29.89M32.55M93.60M
EBITDA30.45M6.67M-25.86M-74.53M-69.08M26.17M
Net Income33.77M9.99M-45.24M-94.10M-89.20M4.64M
Balance Sheet
Total Assets447.83M190.57M194.09M214.32M317.83M366.70M
Cash, Cash Equivalents and Short-Term Investments138.52M99.36M71.66M80.35M154.02M174.83M
Total Debt65.10M54.49M47.73M31.13M26.48M25.18M
Total Liabilities267.64M85.14M120.81M94.35M116.97M73.21M
Stockholders Equity129.85M111.30M71.14M116.13M195.02M283.11M
Cash Flow
Free Cash Flow3.73M2.47M-27.10M-77.18M-22.75M-24.73M
Operating Cash Flow4.03M2.88M-14.05M-75.58M-18.46M262.00K
Investing Cash Flow-6.36M-13.28M-326.00K16.46M-8.36M-16.77M
Financing Cash Flow46.43M37.34M5.68M906.00K54.00K92.84M

Mediwelcome Healthcare Management & Technology Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price1.58

Price Trends

50DMA1.64Negative
100DMA1.66Negative
200DMA1.62Negative

Market Momentum

MACD-0.01Positive
RSI45.73Neutral
STOCH68.06Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2159, the sentiment is Negative. The current price of 1.58 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.64, and below the 200-day MA of 1.62, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 45.73 is Neutral, neither overbought nor oversold. The STOCH value of 68.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2159.

Mediwelcome Healthcare Management & Technology Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:2159 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1830HK:183077OutperformHKD 1.86B10.2643.78%9.96%-14.68%-13.60%
HK:2159HK:215955NeutralHKD 519.86M9.8528.00%―91.32%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:2158HK:215851NeutralHKD 2.41B26.561.88%1.95%16.87%―
HK:9906HK:990651NeutralHKD 936.00M23.425.59%―――
HK:3886HK:388648NeutralHKD 1.10B77.140.48%1.11%-3.26%―
HK:2138HK:213841NeutralHKD 568.90M-1.37-25.36%―-8.94%-140.82%

* Healthcare Sector Average

Performance Comparison

-50%0%50%HK:2159HK:9906HK:1830HK:2138HK:2158HK:3886Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:2159 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:2159Mediwelcome Healthcare Management & Technology Inc.1.580.4135.04%
HK:9906Honliv Healthcare Management Group Co Ltd1.56-0.19-10.86%
HK:1830Perfect Medical Health Management Limited1.460.2015.97%
HK:2138EC Healthcare0.47-0.13-22.50%
HK:2158Yidu Tech, Inc.2.05-2.93-58.81%
HK:3886Town Health International Medical Group Ltd.0.16-0.08-34.41%

Mediwelcome Healthcare Management & Technology Inc. Corporate Events

Mediwelcome Completes HK$84.72 Million Share Placing to Fund Acquisition

Aug 31, 2026

Mediwelcome Healthcare Management & Technology Inc. has completed a placing of 56,480,000 new shares to at least six professional and institutional investors at HK$1.50 per share, raising gross proceeds of HK$84.72 million. The net proceeds of approx...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026